{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:45:37Z","timestamp":1793375137047,"version":"4.5.0"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Cisplatin remains a key chemotherapy for many solid tumors, but its dose-limiting nephrotoxicity affects up to one third of patients and has no effective pharmacologic prevention beyond hydration and magnesium supplementation. Preclinical studies highlight sodium-glucose cotransporter 2 (SGLT2) inhibitors as promising nephroprotective agents during cisplatin therapy, independent of glucose lowering. We conducted a PubMed search using predefined terms related to cisplatin nephrotoxicity and SGLT2 inhibitors, identifying seven nondiabetic rodent studies. Across these models, SGLT2 inhibitors consistently attenuated kidney injury through complementary mechanisms such as suppression of inflammatory, oxidative, and apoptotic pathways; activation of AMP-activated protein kinase\u2013dependent autophagy; reduction of kidney platinum accumulation; and, uniquely, correction of cisplatin-induced hypomagnesemia, a clinically significant complication. Protective effects occurred without compromising cisplatin\u2019s antitumor efficacy\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      . Overall, these findings support SGLT2 inhibitors as a mechanistically versatile strategy that targets key injury pathways in platinum nephrotoxicity. Although prospective clinical application remains untested, the strong biologic rationale, reproducibility across models, and established safety of SGLT2 inhibitors in other populations underscore the urgency of translation. Future clinical trials should incorporate rigorous assessments of kidney function, tubular injury biomarkers, and urinary extracellular vesicle profiling to define the safety, efficacy, and mechanistic insights of SGLT2 inhibitors in cisplatin nephrotoxicity.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0000001194","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:06:06Z","timestamp":1773936366000},"page":"1150-1159","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Cisplatin Nephrotoxicity"],"prefix":"10.34067","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3496-2542","authenticated-orcid":false,"given":"Akash","family":"Mathavan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-834X","authenticated-orcid":false,"given":"Akshay","family":"Mathavan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4097-4606","authenticated-orcid":false,"given":"Chintan V.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"1","key":"B1-20260601","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41581-022-00631-7","article-title":"Cisplatin nephrotoxicity: new insights and therapeutic implications","volume":"19","author":"Tang","year":"2023","journal-title":"Nat Rev Nephrol."},{"key":"B2-20260601","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/967826","article-title":"Pathophysiology of cisplatin-induced acute kidney injury","volume":"2014","author":"Ozkok","year":"2014","journal-title":"Biomed Res Int."},{"issue":"1","key":"B3-20260601","doi-asserted-by":"crossref","first-page":"F161","DOI":"10.1152\/ajprenal.00636.2017","article-title":"Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease","volume":"315","author":"Sharp","year":"2018","journal-title":"Am J Physiol Renal Physiol."},{"issue":"7","key":"B4-20260601","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.08070715","article-title":"Long\u2013term renal outcomes after cisplatin treatment","volume":"11","author":"Latcha","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"B5-20260601","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1124\/jpet.124.002287","article-title":"Understanding cisplatin pharmacokinetics and toxicodynamics to predict and prevent kidney injury","volume":"391","author":"Thompson","year":"2024","journal-title":"J Pharmacol Exp Ther."},{"issue":"12","key":"B6-20260601","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41401-021-00620-9","article-title":"Natural products: potential treatments for cisplatin-induced nephrotoxicity","volume":"42","author":"Fang","year":"2021","journal-title":"Acta Pharmacol Sin."},{"issue":"6","key":"B7-20260601","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/jamaoncol.2025.0756","article-title":"Intravenous magnesium and cisplatin-associated acute kidney injury","volume":"11","author":"Gupta","year":"2025","journal-title":"JAMA Oncol."},{"issue":"8","key":"B8-20260601","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","article-title":"Applications of SGLT2 inhibitors beyond glycaemic control","volume":"20","author":"O\u2019Hara","year":"2024","journal-title":"Nat Rev Nephrol."},{"issue":"4","key":"B9-20260601","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"B10-20260601","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol."},{"key":"B11-20260601","doi-asserted-by":"crossref","first-page":"e077169","DOI":"10.1136\/bmj-2023-077169","article-title":"Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study","volume":"384","author":"Gupta","year":"2024","journal-title":"BMJ."},{"issue":"10","key":"B12-20260601","doi-asserted-by":"crossref","first-page":"100533","DOI":"10.1016\/j.xkme.2022.100533","article-title":"Sodium-glucose cotransporter 2 inhibitors and management of refractory hypomagnesemia without overt urinary magnesium wasting: a report of 2 cases","volume":"4","author":"Shah","year":"2022","journal-title":"Kidney Med."},{"issue":"4","key":"B13-20260601","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1091581813493013","article-title":"Time course of renal proximal tubule injury, reversal, and related biomarker changes in rats following cisplatin administration","volume":"32","author":"McDuffie","year":"2013","journal-title":"Int J Toxicol."},{"key":"B14-20260601","doi-asserted-by":"crossref","first-page":"117171","DOI":"10.1016\/j.taap.2024.117171","article-title":"Cisplatin caused highly delayed cytotoxicity in the immortalized cells derived from S3 segment of mouse kidney proximal tubules","volume":"494","author":"Taguchi","year":"2025","journal-title":"Toxicol Appl Pharmacol."},{"key":"B15-20260601","doi-asserted-by":"crossref","first-page":"127553","DOI":"10.1016\/j.jtemb.2024.127553","article-title":"Nephropathy induced by cisplatin results from mitochondrial disruption, impaired energy metabolism, altered expression of renal transporters, and accumulation of urinary toxins","volume":"86","author":"Zhang","year":"2024","journal-title":"J Trace Elem Med Biol."},{"issue":"6","key":"B16-20260601","doi-asserted-by":"crossref","first-page":"151341","DOI":"10.1016\/j.semnephrol.2023.151341","article-title":"Cisplatin nephrotoxicity: novel insights into mechanisms and preventative strategies","volume":"42","author":"Motwani","year":"2022","journal-title":"Semin Nephrol."},{"issue":"5","key":"B17-20260601","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ki.1984.86","article-title":"Uptake and metabolism of cisplatin by rat kidney","volume":"25","author":"Safirstein","year":"1984","journal-title":"Kidney Int."},{"key":"B18-20260601","doi-asserted-by":"crossref","first-page":"154162","DOI":"10.1016\/j.tox.2025.154162","article-title":"An adverse outcome pathway for DNA adduct formation leading to kidney failure","volume":"515","author":"Barnes","year":"2025","journal-title":"Toxicology."},{"issue":"7","key":"B19-20260601","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/cancers13071572","article-title":"Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations","volume":"13","author":"McSweeney","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"9","key":"B20-20260601","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.freeradbiomed.2011.08.006","article-title":"Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury","volume":"51","author":"Mukhopadhyay","year":"2011","journal-title":"Free Radic Biol Med."},{"issue":"5","key":"B21-20260601","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/ijms25052560","article-title":"Cisplatin nephrotoxicity is critically mediated by the availability of BECLIN1","volume":"25","author":"Bork","year":"2024","journal-title":"Int J Mol Sci."},{"issue":"6","key":"B22-20260601","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1172\/JCI200215606","article-title":"TNF-\u03b1 mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity","volume":"110","author":"Ramesh","year":"2002","journal-title":"J Clin Invest."},{"issue":"6","key":"B23-20260601","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/cr.2011.27","article-title":"Cisplatin ototoxicity involves cytokines and STAT6 signaling network","volume":"21","author":"Kim","year":"2011","journal-title":"Cell Res."},{"issue":"5","key":"B24-20260601","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MNH.0000000000000351","article-title":"Trafficking and regulation of the NKCC2 cotransporter in the thick ascending limb","volume":"26","author":"Mutig","year":"2017","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"4","key":"B25-20260601","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ndt\/gfs499","article-title":"Cisplatin-induced injury of the renal distal convoluted tubule is associated with hypomagnesaemia in mice","volume":"28","author":"van Angelen","year":"2013","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B26-20260601","doi-asserted-by":"crossref","first-page":"e57016","DOI":"10.1371\/journal.pone.0057016","article-title":"The TRPM6\/EGF pathway is downregulated in a rat model of cisplatin nephrotoxicity","volume":"8","author":"Ledeganck","year":"2013","journal-title":"PLoS One."},{"issue":"9","key":"B27-20260601","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1681\/ASN.2021010042","article-title":"Molecular mechanisms of renal magnesium reabsorption","volume":"32","author":"Ellison","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"21","key":"B28-20260601","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMra1510603","article-title":"Magnesium disorders","volume":"390","author":"Touyz","year":"2024","journal-title":"N Engl J Med."},{"issue":"10","key":"B29-20260601","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation."},{"issue":"4","key":"B30-20260601","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab."},{"key":"B31-20260601","doi-asserted-by":"crossref","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med (Lausanne)."},{"issue":"10","key":"B32-20260601","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.3390\/ijms23105371","article-title":"Mitochondria-mediated cardiovascular benefits of sodium-glucose Co-Transporter 2 inhibitors","volume":"23","author":"Dabravolski","year":"2022","journal-title":"Int J Mol Sci."},{"issue":"13","key":"B33-20260601","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2174\/0113816128289350240320063045","article-title":"Cellular and mitochondrial pathways contribute to SGLT2 inhibitors-mediated tissue protection: experimental and clinical data","volume":"30","author":"Sanz","year":"2024","journal-title":"Curr Pharm Des."},{"issue":"2","key":"B34-20260601","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2215\/CJN.09380822","article-title":"Kidney-protective effects of SGLT2 inhibitors","volume":"18","author":"Palmer","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"B35-20260601","doi-asserted-by":"crossref","first-page":"C661","DOI":"10.1152\/ajpcell.00177.2023","article-title":"Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench","volume":"325","author":"Chen","year":"2023","journal-title":"Am J Physiol Cell Physiol."},{"issue":"12","key":"B36-20260601","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.3390\/molecules25122757","article-title":"The off-target effects, electrolyte and mineral disorders of SGLT2i","volume":"25","author":"Cianciolo","year":"2020","journal-title":"Molecules."},{"issue":"5","key":"B37-20260601","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1053\/j.ajkd.2023.11.006","article-title":"Sodium\/glucose cotransporter 2 inhibitors and magnesium homeostasis: a review","volume":"83","author":"Shah","year":"2024","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B38-20260601","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00210-018-1564-7","article-title":"Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice","volume":"392","author":"Abdelrahman","year":"2019","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"issue":"9","key":"B39-20260601","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1007\/s00210-024-03088-6","article-title":"Empagliflozin protective effects against cisplatin-induced acute nephrotoxicity by interfering with oxidative stress and inflammation in wistar rats","volume":"397","author":"Farrokh-Eslamlou","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"issue":"1","key":"B40-20260601","doi-asserted-by":"crossref","first-page":"90","DOI":"10.32725\/jab.2019.003","article-title":"Pre-treatment with empagliflozin ameliorates cisplatin induced acute kidney injury by suppressing apoptosis","volume":"17","author":"Abd Elmaaboud","year":"2019","journal-title":"J Appl Biomed."},{"key":"B41-20260601","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.2147\/DDDT.S561268","article-title":"Ameliorative effect of empagliflozin and linagliptin on cisplatin-induced nephrotoxicity and cardiotoxicity by reducing oxidative stress","volume":"19","author":"Alharbi","year":"2025","journal-title":"Drug Des Devel Ther."},{"issue":"1","key":"B42-20260601","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41420-021-00801-9","article-title":"Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells","volume":"8","author":"Park","year":"2022","journal-title":"Cell Death Discov."},{"issue":"4","key":"B43-20260601","doi-asserted-by":"crossref","first-page":"F1041","DOI":"10.1152\/ajprenal.00512.2019","article-title":"Canagliflozin reduces cisplatin uptake and activates Akt to protect against cisplatin-induced nephrotoxicity","volume":"318","author":"Song","year":"2020","journal-title":"Am J Physiol Renal Physiol."},{"issue":"9","key":"B44-20260601","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1681\/ASN.0000000700","article-title":"SGLT2 inhibitors blunt kidney magnesium wasting in acute cisplatin-induced hypomagnesemia with effects on the thick ascending limb and distal convoluted tubule","volume":"36","author":"Jesus","year":"2025","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"B45-20260601","doi-asserted-by":"crossref","first-page":"100697","DOI":"10.1016\/j.xkme.2023.100697","article-title":"SGLT2 inhibitors in management of severe hypomagnesemia in patients without diabetes: a report of 4 cases","volume":"5","author":"Shah","year":"2023","journal-title":"Kidney Med."},{"issue":"6","key":"B46-20260601","first-page":"e62546","article-title":"The use of amiloride and sodium-glucose cotransporter 2 inhibitors in cisplatin-induced hypomagnesemia: a case report and review of the literature","volume":"16","author":"Heleno","year":"2024","journal-title":"Cureus"},{"issue":"11","key":"B47-20260601","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1016\/j.ekir.2025.08.012","article-title":"Dapagliflozin-associated resolution of acute carboplatin-induced hypomagnesemia-exploration of TRPM6\/7 channel activity","volume":"10","author":"Shah","year":"2025","journal-title":"Kidney Int Rep."},{"issue":"582","key":"B48-20260601","doi-asserted-by":"crossref","first-page":"eabd6299","DOI":"10.1126\/scitranslmed.abd6299","article-title":"Mechanism and reversal of drug-induced nephrotoxicity on a chip","volume":"13","author":"Cohen","year":"2021","journal-title":"Sci Transl Med."},{"issue":"11","key":"B49-20260601","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.21873\/anticanres.17858","article-title":"Efficacy of SGLT-2 inhibitors in preventing cisplatin-induced kidney injury in patients with diabetes","volume":"45","author":"Ishigami","year":"2025","journal-title":"Anticancer Res."},{"key":"B50-20260601","doi-asserted-by":"crossref","first-page":"126798","DOI":"10.1016\/j.jtemb.2021.126798","article-title":"Role of ferroptosis in cisplatin-induced acute nephrotoxicity in mice","volume":"67","author":"Ikeda","year":"2021","journal-title":"J Trace Elem Med Biol."},{"key":"B51-20260601","doi-asserted-by":"crossref","first-page":"1700004","DOI":"10.3389\/fimmu.2025.1700004","article-title":"Targeting ferroptosis: novel therapeutic approaches and intervention strategies for kidney diseases","volume":"16","author":"Luo","year":"2025","journal-title":"Front Immunol."},{"issue":"2","key":"B52-20260601","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1681\/ASN.2019060570","article-title":"Drugs repurposed as antiferroptosis agents suppress organ damage, including AKI, by functioning as lipid peroxyl radical scavengers","volume":"31","author":"Mishima","year":"2020","journal-title":"J Am Soc Nephrol."},{"key":"B53-20260601","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2022.12.088","article-title":"Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK\/NRF2 pathway","volume":"195","author":"Lu","year":"2023","journal-title":"Free Radic Biol Med."},{"issue":"1","key":"B54-20260601","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1038\/s41598-025-91278-4","article-title":"Dapagliflozin inhibits ferroptosis and ameliorates renal fibrosis in diabetic C57BL\/6J mice","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep."},{"issue":"7-9","key":"B55-20260601","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1089\/ars.2022.0169","article-title":"Dapagliflozin alleviates diabetic kidney disease via hypoxia inducible factor 1\u03b1\/heme oxygenase 1-mediated ferroptosis","volume":"40","author":"Wang","year":"2024","journal-title":"Antioxid Redox Signal."},{"issue":"1","key":"B56-20260601","doi-asserted-by":"crossref","first-page":"20386","DOI":"10.1038\/s41598-024-71416-0","article-title":"SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis","volume":"14","author":"Hirashima","year":"2024","journal-title":"Sci Rep."},{"key":"B57-20260601","first-page":"1767","article-title":"Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer","volume":"66","author":"Schilsky","year":"1982","journal-title":"Cancer Treat Rep."},{"issue":"9","key":"B58-20260601","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1681\/ASN.0000000806","article-title":"Sodium-glucose cotransporter 2 inhibitors","volume":"36","author":"Nickerson","year":"2025","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B59-20260601","doi-asserted-by":"crossref","first-page":"F550","DOI":"10.1152\/ajprenal.00136.2018","article-title":"Fructose acutely stimulates NKCC2 activity in rat thick ascending limbs by increasing surface NKCC2 expression","volume":"316","author":"Ares","year":"2019","journal-title":"Am J Physiol Renal Physiol."},{"issue":"1","key":"B60-20260601","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2021121544","article-title":"Glucose\/fructose delivery to the distal nephron activates the sodium-chloride cotransporter via the calcium-sensing receptor","volume":"34","author":"Bahena-Lopez","year":"2023","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B61-20260601","doi-asserted-by":"crossref","first-page":"F692","DOI":"10.1152\/ajprenal.00053.2022","article-title":"SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in dahl SS rats","volume":"322","author":"Kravtsova","year":"2022","journal-title":"Am J Physiol Renal Physiol."},{"issue":"12","key":"B62-20260601","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000543336","article-title":"Dapagliflozin treatment attenuates the interaction between the renal sodium chloride Co-Transporter and ezrin in hypertensive diabetic db\/db mice","volume":"149","author":"Gholam","year":"2025","journal-title":"Nephron."},{"issue":"9","key":"B63-20260601","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1681\/ASN.0000000762","article-title":"Acute cisplatin nephrotoxicity, sodium-glucose cotransporter 2 inhibitors, and benefits beyond magnesium","volume":"36","author":"Shah","year":"2025","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"B64-20260601","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1681\/ASN.0000000763","article-title":"Authors\u2019 reply: acute cisplatin nephrotoxicity, sodium-glucose cotransporter 2 inhibitors, and benefits beyond magnesium","volume":"36","author":"Luchi","year":"2025","journal-title":"J Am Soc Nephrol."},{"issue":"10246","key":"B65-20260601","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(20)30540-7","article-title":"The link between kidney disease and cancer: complications and treatment","volume":"396","author":"Malyszko","year":"2020","journal-title":"Lancet."},{"issue":"6","key":"B66-20260601","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer."},{"issue":"15","key":"B67-20260601","doi-asserted-by":"crossref","first-page":"e33505","DOI":"10.1097\/MD.0000000000033505","article-title":"Malignancy diseases and kidneys: a nephrologist prospect and updated review","volume":"102","author":"Habas","year":"2023","journal-title":"Medicine."},{"issue":"1","key":"B68-20260601","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jcsm.12012","article-title":"Influence of cancer cachexia on drug liver metabolism and renal elimination in rats","volume":"6","author":"Cvan Trobec","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"5","key":"B69-20260601","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCRESAHA.124.324823","article-title":"SGLT2 inhibitors act independently of SGLT2 to confer benefit for HFrEF in mice","volume":"135","author":"Berger","year":"2024","journal-title":"Circ Res."},{"key":"B70-20260601","doi-asserted-by":"crossref","first-page":"217958","DOI":"10.1016\/j.canlet.2025.217958","article-title":"Comparative safety of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in patients receiving anti-neoplastic therapies for cancer: an inverse probability treatment weighting analysis","volume":"632","author":"Lyu","year":"2025","journal-title":"Cancer Lett."},{"issue":"4","key":"B71-20260601","doi-asserted-by":"crossref","first-page":"F369","DOI":"10.1152\/ajprenal.00127.2014","article-title":"Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation","volume":"307","author":"Solanki","year":"2014","journal-title":"Am J Physiol Renal Physiol."},{"issue":"6","key":"B72-20260601","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1681\/ASN.0000000705","article-title":"Toward assessment of tubular function in kidney disease","volume":"36","author":"Beckmann","year":"2025","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"B73-20260601","doi-asserted-by":"crossref","first-page":"e12093","DOI":"10.1002\/jev2.12093","article-title":"Urinary extracellular vesicles: a position paper by the urine task force of the international society for extracellular vesicles","volume":"10","author":"Erdbr\u00fcgger","year":"2021","journal-title":"J Extracell Vesicles."},{"issue":"6","key":"B74-20260601","doi-asserted-by":"crossref","first-page":"C1439","DOI":"10.1152\/ajpcell.00349.2023","article-title":"Exploring the role of urinary extracellular vesicles in kidney physiology, aging, and disease progression","volume":"325","author":"Grange","year":"2023","journal-title":"Am J Physiol Cell Physiol."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:03:07Z","timestamp":1786478587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001194"}},"subtitle":["A Mechanistic Review"],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000001194","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"2025-10-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}